肽类药物市场－全球产业规模、份额、趋势、机会及预测（按应用、类型、製造商、给药途径、合成技术、地区和竞争格局划分，2021-2031年）

全球胜肽类药物市场预计将以强劲的速度成长，预计到 2031 年将达到 967.3 亿美元，而 2025 年为 569 亿美元，复合年增长率为 9.25%。

这些疗法被定义为由短氨基酸链组成的选择性讯号分子，因其能够高效、低毒性地调节特定的生理功能而备受重视。市场扩张主要受慢性代谢性疾病（尤其是糖尿病和肥胖症）日益普遍的推动，这导致对标靶受体促效剂的需求激增。此外，合成製造技术的进步降低了生产门槛，从而扩大了商业性应用范围。例如，美国化学学会 (ACS) 报告称，美国食品药物管理局 (FDA) 在 2023 年核准了9 种胜肽和寡核苷酸类疗法，占当年新药核准总数的 16%。

儘管前景乐观，但肽类药物产业在药物传递和稳定性方面仍面临诸多挑战。肽类药物的口服生物有效性通常较低，且容易受到酵素降解，因此往往需要频繁地进行侵入性注射。这种肠外给药的需求增加了患者依从性，并限制了胜肽类治疗方法在慢性病治疗中的广泛应用。因此，如何克服这些药物动力学限制仍然是该领域面临的一项重大挑战，因为该领域正致力于提高长期治疗方法的便利性和疗效。

市场驱动因素

全球代谢性疾病和慢性疾病（尤其是第2型糖尿病和肥胖症）发生率的不断上升，是推动市场扩张的主要因素。日益加重的疾病负担使得临床上更加关注Glucagon-Like Peptide-1(GLP-1) 受体促效剂，这类药物以其调节食慾和促进胰岛素分泌的作用而闻名。因此，大型製药公司在代谢肽领域实现了显着的收入成长，这也促使他们扩大生产规模。例如，诺和诺德公司2023年的年度报告预测，截至2024年2月，其肥胖症治疗部门的销售额（经外汇后）将增长154%，达到416亿丹麦克朗，这证实了这些疗法在文明病管理中的重要作用，以及它们凭藉生物目标分子所取得的商业性成功。

第二个驱动因素是生物製药研发的积极扩张以及旨在获取创新肽类资产的策略性併购。大型製药公司正积极收购专业生物技术公司，以获得下一代促效剂和三重促效剂，这项策略可以降低早期风险并加速产品上市。值得注意的是，2023年12月，罗氏同意以27亿美元的预付款收购胜肽类药物开发商Carmot Therapeutics，显示该产业正致力于拓展传统胰岛素以外的产品线。为了支持这一成长，製造商也在基础设施方面投入大量资金。 2023年11月，礼来公司宣布投资25亿美元在德国新建一座生产设施，以增强供给能力，特别是注射用胜肽类药物的供应能力。

市场挑战

全球肽类药物市场面临的主要障碍是肽分子固有的不稳定性及其导致的药物递送难题。肽类药物易受胃肠道和循环系统中酵素的快速降解，导致口服生物生物有效性有限且半衰期短。因此，通常需要皮下或静脉注射等侵入性给药方式，以确保药物能有效到达标靶。这种对频繁注射的依赖严重影响了患者的依从性，尤其对于需要长期治疗的慢性疾病而言，从而限制了目标患者群体，并阻碍了整体市场渗透。

此外，开发稳定有效的递送系统所面临的复杂性也减缓了新产品通过监管审批流程的进程。这些分子製剂的研发挑战也反映在核准统计数据中。根据监管事务专业人员协会（RAPS）统计，2024年仅有两种新型胜肽类疗法将获得FDA核准，仅占当年核准的50种新分子实体的4%。与传统小分子化合物相比，如此低的核准率凸显了研发人员在解决稳定性问题方面持续面临的困难，并直接限制了成功进入商业市场的新型治疗方法的数量。

市场趋势

将人工智慧应用于胜肽类药物研发正在改变研发格局，有效解决了优化膜渗透性和代谢稳定性等长期存在的难题。先进的运算平台能够快速筛检庞大的虚拟化合物库，在物理合成之前即可辨识出具有优异结合亲和性和药物动力学特性的候选化合物。这项技术进步使研发人员能够缩短药物研发週期，并降低早期开发阶段常见的高失败率。例如，Bioduro 于 2025 年 8 月宣布与 Atombeat 建立策略合作伙伴关係，共同部署一个人工智慧驱动的平台，该平台能够评估超过一兆种潜在的胜肽类化合物，从而加速筛选出有效的治疗候选药物。

同时，新一代胜肽-药物偶联物（PDCs）的出现标誌着标靶肿瘤治疗领域的重大进步。我们正从简单的受体促效剂转向复杂的药物传递系统，这些系统能够将细胞毒性物质和放射性物质直接输送到癌细胞。与抗体药物复合体相比，PDCs具有组织穿透深度深、全身清除速度快等优势，有助于在维持对固态肿瘤疗效的同时，最大限度地减少脱靶毒性。放射性配体疗法和创新连结子技术的临床研究数量显着增加，也印证了这一趋势。根据药明康德2025年6月发布的报告，2024年将启动超过30项放射性配体-药物偶联物的临床试验，与前五年相比增加了三倍。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球胜肽类治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依应用领域（癌症、代谢性疾病、心血管疾病、呼吸系统疾病、消化系统疾病、感染疾病、疼痛、皮肤病、神经系统疾病、肾臟疾病、其他疾病）
  • 按类型（学名药、药物研发）
  • 依生产方式（自主生产、外包）
  • 依给药途径（肠外、口服、肺部、黏膜、其他）
  • 透过合成技术（固相胜肽合成（SPPS）、液相胜肽合成（LPPS）、混合技术）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美胜肽类药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲胜肽类药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区胜肽类药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲胜肽类药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲胜肽类药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球胜肽类药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Eli Lilly and Co.
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Co Ltd.
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• F Hoffmann-La Roche AG
• Novartis AG
• Novo Nordisk A/S

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Peptide Therapeutics Market is projected to experience robust growth, advancing from a valuation of USD 56.90 Billion in 2025 to USD 96.73 Billion by 2031, reflecting a compound annual growth rate of 9.25%. These therapeutics, defined as selective signaling molecules comprised of short amino acid chains, are valued for their ability to regulate specific physiological functions with high potency and minimal toxicity. The market's expansion is largely fueled by the increasing prevalence of chronic metabolic disorders, particularly diabetes and obesity, which has surged the demand for targeted receptor agonists. Additionally, advancements in synthetic manufacturing techniques are reducing production hurdles, thereby enabling wider commercial availability. Highlighting this momentum, the American Chemical Society reported that in 2023, the FDA approved nine peptide and oligonucleotide therapeutics, accounting for 16% of the year's total new drug approvals.

Despite this positive outlook, the industry confronts significant obstacles regarding drug delivery and stability. Peptides generally suffer from low oral bioavailability and are quickly cleared from the bloodstream due to enzymatic degradation, often requiring frequent invasive injections. This necessity for parenteral administration complicates patient compliance and restricts the broader application of peptide-based therapies in managing chronic conditions. Consequently, overcoming these pharmacokinetic limitations remains a pivotal challenge for the sector as it seeks to enhance the convenience and effectiveness of long-term treatment regimens.

Market Driver

The surging global incidence of metabolic and chronic conditions, particularly type 2 diabetes and obesity, acts as a primary catalyst for market expansion. This increasing disease burden has directed clinical attention toward Glucagon-like peptide-1 (GLP-1) receptor agonists, known for their efficacy in regulating appetite and insulin secretion. As a result, major pharmaceutical companies are seeing substantial revenue growth from their metabolic peptide divisions, prompting a need for scaled-up production. For instance, Novo Nordisk's 2023 Annual Report revealed that sales within its Obesity Care division rose by 154% at constant exchange rates to 41.6 billion Danish kroner in February 2024, underscoring the vital role these therapeutics play in lifestyle disease management and the commercial success derived from these targeted biological molecules.

A secondary driver is the vigorous expansion of biopharmaceutical research and development, coupled with strategic mergers and acquisitions designed to secure innovative peptide assets. Major pharmaceutical corporations are actively acquiring specialized biotech firms to gain access to next-generation dual and triple agonists, a strategy that mitigates early-stage risks and accelerates product launches. Notably, in December 2023, Roche agreed to acquire the peptide developer Carmot Therapeutics for an upfront payment of 2.7 billion US dollars, demonstrating the industry's dedication to broadening pipelines beyond traditional insulin. To support this growth, manufacturers are also heavily investing in infrastructure; in November 2023, Eli Lilly and Company pledged 2.5 billion dollars to build a new manufacturing facility in Germany, specifically to enhance its parenteral peptide supply capabilities.

Market Challenge

The primary obstacle impeding the Global Peptide Therapeutics Market is the intrinsic instability of peptide molecules combined with significant drug delivery difficulties. Peptides are prone to rapid degradation by enzymes in the gastrointestinal tract and circulation, leading to limited oral bioavailability and brief half-lives. Consequently, invasive administration methods such as subcutaneous or intravenous injections are often required to ensure the medication reaches its intended target with adequate potency. This reliance on frequent injections poses a substantial hurdle to patient adherence, especially for chronic conditions requiring long-term treatment, which in turn restricts the addressable patient base and hampers overall market penetration.

Furthermore, the complexity involved in developing stable and effective delivery systems retards the progress of new products through regulatory pathways. The challenge of formulating these molecules is reflected in approval statistics; according to the Regulatory Affairs Professionals Society, only two novel peptide therapeutics received FDA approval in 2024, comprising a mere 4% of the 50 new molecular entities authorized that year. This low approval rate relative to traditional small molecules highlights the enduring struggle developers face in resolving stability concerns, directly limiting the number of new therapies that successfully enter the commercial market.

Market Trends

The incorporation of artificial intelligence into peptide discovery is transforming the research and development landscape by addressing longstanding challenges such as optimizing membrane permeability and metabolic stability. Advanced computational platforms now facilitate the rapid screening of extensive virtual libraries, allowing researchers to pinpoint candidates with superior binding affinity and pharmacokinetic properties prior to physical synthesis. This technological evolution enables developers to shorten discovery schedules and decrease the high failure rates typical of early-stage development. Illustrating this trend, BioDuro announced a strategic partnership with Atombeat in August 2025, deploying an AI-driven platform capable of evaluating over one trillion potential peptide compounds to accelerate the identification of viable therapeutic candidates.

Simultaneously, the emergence of next-generation Peptide Drug Conjugates (PDCs) marks a significant advancement in targeted oncology, transitioning from simple receptor agonists to complex delivery systems that transport cytotoxic or radioactive agents directly to cancer cells. Compared to antibody-drug conjugates, PDCs offer advantages such as deeper tissue penetration and more rapid systemic clearance, which help minimize off-target toxicity while maintaining potency against solid tumors. This trend is highlighted by a marked increase in clinical efforts surrounding radioligand therapies and innovative linker technologies; a June 2025 report by WuXi AppTec noted that over 30 radioligand drug conjugate clinical trials were initiated in 2024, representing a threefold increase over the previous five years.

Key Market Players

• Eli Lilly and Co.
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Co Ltd.
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• F Hoffmann-La Roche AG
• Novartis AG
• Novo Nordisk A/S

Report Scope

In this report, the Global Peptide Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Therapeutics Market, By Application

• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others

Peptide Therapeutics Market, By Type

• Generic
• Innovative

Peptide Therapeutics Market, By Type of Manufacturers

• In-house
• Outsourced

Peptide Therapeutics Market, By Route of Administration

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

Peptide Therapeutics Market, By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Peptide Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Therapeutics Market.

Available Customizations:

Global Peptide Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others)
  • 5.2.2. By Type (Generic, Innovative)
  • 5.2.3. By Type of Manufacturers (In-house, Outsourced)
  • 5.2.4. By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others)
  • 5.2.5. By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Peptide Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Type
  • 6.2.3. By Type of Manufacturers
  • 6.2.4. By Route of Administration
  • 6.2.5. By Synthesis Technology
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Peptide Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Type of Manufacturers
      • 6.3.1.2.4. By Route of Administration
      • 6.3.1.2.5. By Synthesis Technology
  • 6.3.2. Canada Peptide Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Type of Manufacturers
      • 6.3.2.2.4. By Route of Administration
      • 6.3.2.2.5. By Synthesis Technology
  • 6.3.3. Mexico Peptide Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Type of Manufacturers
      • 6.3.3.2.4. By Route of Administration
      • 6.3.3.2.5. By Synthesis Technology

7. Europe Peptide Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Type
  • 7.2.3. By Type of Manufacturers
  • 7.2.4. By Route of Administration
  • 7.2.5. By Synthesis Technology
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Peptide Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Type of Manufacturers
      • 7.3.1.2.4. By Route of Administration
      • 7.3.1.2.5. By Synthesis Technology
  • 7.3.2. France Peptide Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Type of Manufacturers
      • 7.3.2.2.4. By Route of Administration
      • 7.3.2.2.5. By Synthesis Technology
  • 7.3.3. United Kingdom Peptide Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Type of Manufacturers
      • 7.3.3.2.4. By Route of Administration
      • 7.3.3.2.5. By Synthesis Technology
  • 7.3.4. Italy Peptide Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Type of Manufacturers
      • 7.3.4.2.4. By Route of Administration
      • 7.3.4.2.5. By Synthesis Technology
  • 7.3.5. Spain Peptide Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Type of Manufacturers
      • 7.3.5.2.4. By Route of Administration
      • 7.3.5.2.5. By Synthesis Technology

8. Asia Pacific Peptide Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Type
  • 8.2.3. By Type of Manufacturers
  • 8.2.4. By Route of Administration
  • 8.2.5. By Synthesis Technology
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Peptide Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Type of Manufacturers
      • 8.3.1.2.4. By Route of Administration
      • 8.3.1.2.5. By Synthesis Technology
  • 8.3.2. India Peptide Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Type of Manufacturers
      • 8.3.2.2.4. By Route of Administration
      • 8.3.2.2.5. By Synthesis Technology
  • 8.3.3. Japan Peptide Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Type of Manufacturers
      • 8.3.3.2.4. By Route of Administration
      • 8.3.3.2.5. By Synthesis Technology
  • 8.3.4. South Korea Peptide Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Type of Manufacturers
      • 8.3.4.2.4. By Route of Administration
      • 8.3.4.2.5. By Synthesis Technology
  • 8.3.5. Australia Peptide Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Type of Manufacturers
      • 8.3.5.2.4. By Route of Administration
      • 8.3.5.2.5. By Synthesis Technology

9. Middle East & Africa Peptide Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Type
  • 9.2.3. By Type of Manufacturers
  • 9.2.4. By Route of Administration
  • 9.2.5. By Synthesis Technology
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Peptide Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Type of Manufacturers
      • 9.3.1.2.4. By Route of Administration
      • 9.3.1.2.5. By Synthesis Technology
  • 9.3.2. UAE Peptide Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Type of Manufacturers
      • 9.3.2.2.4. By Route of Administration
      • 9.3.2.2.5. By Synthesis Technology
  • 9.3.3. South Africa Peptide Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Type of Manufacturers
      • 9.3.3.2.4. By Route of Administration
      • 9.3.3.2.5. By Synthesis Technology

10. South America Peptide Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Type
  • 10.2.3. By Type of Manufacturers
  • 10.2.4. By Route of Administration
  • 10.2.5. By Synthesis Technology
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Peptide Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Type of Manufacturers
      • 10.3.1.2.4. By Route of Administration
      • 10.3.1.2.5. By Synthesis Technology
  • 10.3.2. Colombia Peptide Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Type of Manufacturers
      • 10.3.2.2.4. By Route of Administration
      • 10.3.2.2.5. By Synthesis Technology
  • 10.3.3. Argentina Peptide Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Type of Manufacturers
      • 10.3.3.2.4. By Route of Administration
      • 10.3.3.2.5. By Synthesis Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Peptide Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eli Lilly and Co.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Amgen Inc.
• 15.4. Takeda Pharmaceutical Co Ltd.
• 15.5. AstraZeneca Pharmaceuticals LP
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Sanofi S.A.
• 15.8. F Hoffmann-La Roche AG
• 15.9. Novartis AG
• 15.10. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer